AWMGS launches 3 new genomic services for breast cancer patients

AWMGS are pleased to announce the launch of 3 new genomic services for breast cancer patients.  The services are as follows:

1.  Circulating tumour DNA (ctDNA) ESR1 testing in oestrogen receptor (ER)-positive HER2-negative locally advanced or metastatic breast cancer to enable access to Elacestrant. 

2. AKT1, PIK3CA and PTEN gene targets added and eligibility criteria update to the breast cancer tumour service using FFPE tissue.

3. Germline BRCA1 and BRCA2 testing now available for late stage breast cancer patients in relation to PARP inhibitor (Talazoparib and Olaparib) treatment decisions

    

Request forms for these services can be found here. 

Clinical Guidance document for each of the services can be found here 

Any questions regarding any of these services can be sent to This email address is being protected from spambots. You need JavaScript enabled to view it.